Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 3.15 GBp
Change Today +0.10 / 3.28%
Volume 780.1K
VRP On Other Exchanges
As of 11:30 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VRP) Snapshot

3.05 GBp
Previous Close
3.05 GBp
Day High
3.33 GBp
Day Low
3.05 GBp
52 Week High
06/12/15 - 6.88 GBp
52 Week Low
12/8/14 - 1.20 GBp
Market Cap
Average Volume 10 Days
-0.0050 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VERONA PHARMA PLC (VRP)

Related News

No related news articles were found.

verona pharma plc (VRP) Related Businessweek News

No Related Businessweek News Found

verona pharma plc (VRP) Details

Verona Pharma plc, a clinical stage biopharmaceutical company, engages in the research, discovery, and development of therapeutic drugs for the treatment of acute and chronic respiratory diseases in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual phosphodiesterase 3 and 4 inhibitor that has completed Phase I and II clinical trials used for the treatment of chronic obstructive pulmonary disease and asthma, as well as in pre-clinical testing for the treatment of cystic fibrosis. It is also developing novel anti-inflammatory polysaccharides (NAIPs) that are in basic research phase to treat various respiratory and inflammatory diseases. The company is based in London, United Kingdom.

11 Employees
Last Reported Date: 05/13/15

verona pharma plc (VRP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 261.7K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 47.5K GBP
Compensation as of Fiscal Year 2014.

verona pharma plc (VRP) Key Developments

Verona Pharma plc Announces Completion of Patient Enrolment in RPL554 PhIIa Studies

Verona Pharma plc announced it has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators. Headline data is expected First Quarter 2016 for the asthma study and Second Quarter 2016 for the COPD combination study. RPL554 is a novel inhaled PDE3/PDE4 inhibitor with anti-inflammatory as well as bronchodilatory properties, currently in development as a nebulised treatment for acute exacerbations in COPD patients in a hospital or home-care setting. The nebulised bronchodilator market was worth approximately $1 billion in 2014 in the US.

Verona Pharma Kicks Off Phase IIa Trial of RPL554 as Part of COPD Combination Therapy

Verona Pharma Plc announced that it had commenced dosing in a Phase IIa trial evaluating its inhaled PDE3/PDE4 inhibitor RPL554 as an adjunct to standard reliever therapies in patients with chronic obstructive pulmonary disease (COPD). Verona Pharma plans to enroll up to 30 subjects for the study, which will seek to determine if RPL554 produces an additive bronchodilator effect when administered alongside standard of care bronchodilators in COPD patients. The company expects to report headline results from the combination study in the second quarter of 2016.

Verona Pharma plc Announces Positive Headline Data from RPL554 Study

Verona Pharma plc announced encouraging positive headline data of the third and final part (part C) of a randomized, double blind, placebo controlled Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) clinical study in stable chronic obstructive pulmonary disease (COPD) patients. This study uses a new proprietary and commercially scalable nebulised suspension formulation of the Company's lead pipeline drug, RPL554.1,2 The primary objective of this part of the study was to show the safety and tolerability of the new drug formulation in stable COPD patients with moderate severity of disease. Measurement of lung function using FEV14 was included. Evaluation of the full data set is ongoing and will be presented in an appropriate scientific, peer-reviewed forum at a later date. In the third part of the trial, nebulised RPL554, a novel dual PDE3/PDE4 inhibitor, was administered twice daily using a new proprietary, commercially scalable, suspension formulation to stable COPD patients with moderate disease severity for up to five-and-a-half consecutive days at doses significantly in excess of the previously used active dose. Patients withheld their regular bronchodilator therapy for the duration of the treatment phase of the study. The study met its primary objective and all doses of RPL554 were found to be well tolerated. As with earlier parts of the trial, which were conducted in healthy volunteers, there were no reports of serious adverse events and the adverse event profile was similar to that seen with placebo. In particular, there was an absence of gastro-intestinal or cardiovascular adverse events. Lung function, as measured by peak FEV1, was increased in all dose groups and ranged between 199-257ml over placebo suggesting a clinically meaningful bronchodilator effect which will be confirmed in Phase IIb studies. In the high dose there was a small increase in heart rate as might be expected from the pharmacology of the product. The new commercially scalable formulation of RPL554 results in a uniform suspension of RPL554 and was designed to provide improved tolerability, allowing higher doses of RPL554 to be inhaled, yielding an optimized bronchodilator effect than with the previous prototype, solution formulation. Additionally the new formulation offers potential for improvements in convenience and compliance. Data to date supports this profile, suggesting a twice daily dosing regimen and is consistent with a longer residence time of the drug in lung tissue and slower release into the blood than with the original formulation. In addition, the commercial viability of the new formulation is underlined by significantly improved stability compared to the previous formulation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRP:LN 3.15 GBp +0.10

VRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VRP.
View Industry Companies

Industry Analysis


Industry Average

Valuation VRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VERONA PHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at